

# Resource Summary Report

Generated by [dkNET](#) on Aug 3, 2026

## Recombinant Anti-MelanA antibody [EPR20380]

RRID:AB\_2889292

Type: Antibody

---

### Proper Citation

Abcam Cat# ab210546, RRID:AB\_2889292

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2889292](http://antibodyregistry.org/AB_2889292)

**Proper Citation:** Abcam Cat# ab210546, RRID:AB\_2889292

**Target Antigen:** MelanA

**Clonality:** recombinant monoclonal

**Antibody Name:** Recombinant Anti-MelanA antibody [EPR20380]

**Description:** This recombinant monoclonal targets MelanA

**Clone ID:** EPR20380

**Antibody ID:** AB\_2889292

**Vendor:** Abcam

**Catalog Number:** ab210546

**Record Creation Time:** 20250819T215530+0000

**Record Last Update:** 20250820T003232+0000

---

### Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-MelanA antibody [EPR20380].

No alerts have been found for Recombinant Anti-MelanA antibody [EPR20380].

---

### Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Lucotti S, et al. (2025) Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. *Cell*, 188(6), 1642.

Srour N, et al. (2022) PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. *Cell reports*, 38(13), 110582.

Choi YS, et al. (2022) Topical therapy for regression and melanoma prevention of congenital giant nevi. *Cell*, 185(12), 2071.

Rosenbaum SR, et al. (2021) SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. *Cell reports*, 37(10), 110085.